Comparative Pharmacology
Head-to-head clinical analysis: AMBENYL versus TESSALON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMBENYL versus TESSALON.
AMBENYL vs TESSALON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AMBENYL is a combination product containing codeine (opioid agonist) and bromodiphenhydramine (antihistamine). Codeine binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception; bromodiphenhydramine antagonizes histamine H1 receptors, producing antitussive and sedative effects.
Benzonatate is a local anesthetic structurally related to tetracaine that inhibits pulmonary stretch receptors and reduces the cough reflex by decreasing the sensitivity of vagal afferent fibers in the respiratory tract.
Each 5 mL contains codeine phosphate 10 mg and diphenhydramine hydrochloride 12.5 mg. Adults: 10 mL (2 teaspoonfuls) orally every 4-6 hours as needed; maximum 40 mL per day.
100 mg orally three times daily as needed for cough. Maximum 600 mg/day.
None Documented
None Documented
Codeine: 2.5-3.5 h (terminal) with CYP2D6 poor metabolizers up to 6 h. Guaifenesin: 1-2 h.
Terminal elimination half-life is approximately 12-15 hours in adults; significant interindividual variability. No accumulation with q6h dosing.
Renal: 60% unchanged codeine, 20% codeine-6-glucuronide; biliary/fecal: 20% as metabolites. Guaifenesin: renal 95% as unchanged drug and metabolites.
Renal: <5% unchanged; primary route is hepatic metabolism with metabolites excreted renally and fecally; exact biliary/fecal % not established in humans.
Category C
Category C
Antitussive/Antihistamine Combination
Antitussive